Molecular starts Phase 2 Zemiva trial

Molecular Insight Pharmaceuticals Inc. announced today that it has initiated a Phase 2 trial with Zemiva, a treatment designed to detect heart problems.

The Cambridge company that the trial with Zemiva is for the diagnosis of cardiac ischemia, or lack of sufficient blood supply to an area of the heart, in patients with suspected Acute Coronary Syndrome (ACS) in the emergency department setting.

Zemiva, the company said, is a metabolic, molecular imaging pharmaceutical that has previously demonstrated the ability to detect cardiac ischemia up to 30 hours after an ischemic event, as compared to currently available techniques, which are limited to an approximate two-hour imaging window.
(By Chris Reidy, Globe staff)

•  Previous Entry
• Next Entry